Genetic testing offers the opportunity to identify sources of inter-individual variability in drug disposition and response, with the goal of individualizing therapy (drug selection and dose) and improving patient and public health outcomes. A small number of pharmacogenetic tests are already in clinical use, and other promising examples are emerging, including tests to improve the safety of warfarin, tamoxifen and tacrolimus therapy. Despite this promise, most studies have been undertaken in resource-intensive, tertiary care centers and their relevance for rural health care practice is unknown. Information gaps are especially notable for Alaska Native and American Indian (AI/AN) communities living in rural locations;addressing these gaps requires attention to scientific, health service and cultural issues. We lack knowledge about relevant genetic and environmental variation within indigenous populations of the US, limiting our ability to inform the design and implementation of pharmacogenetic testing services for these groups. In addition, little is known about potential cultural barriers to genetic research within indigenous communities that might delay this research agenda or limit receptiveness to pharmacogenetics, or about the resources that would be needed for optimal implementation of this clinical approach. With these uncertainties and knowledge gaps in mind, we propose to create a new Center on Pharmacogenetics in Rural and Underserved Populations. This Center will work in partnership with indigenous communities in Anchorage and the Yukon-Kuskowkim delta in Alaska and in northwestern Montana, and with rural providers in these locations and in rural Washington, to ensure that there is adequate community understanding, biological knowledge, and medical infrastructure to respond appropriately to national recommendations or mandates related to pharmacogenetics. Our Center will utilize community-based participatory research methods to evaluate community and clinical perspectives on pharmacogenetics;pursue foundational research in AI/AN and rural communities related to genetic variation and response to warfarin, tamoxifen and tacrolimus therapy;evaluate gene-environment interactions related to coagulation factors in one indigenous community;and lay the groundwork for a research infrastructure linking AI/AN communities rural practices to pharmacogenetics researchers.

Public Health Relevance

Completion of the specific aims proposed in this multi-disciplinary, multi-cultural grant application could improve our understanding of pharmacogenetic variability and enhance drug safety/efficacy in American Indian and Alaska Native peoples, by addressing major scientific knowledge gaps and potential cultural/structural barriers to pharmacogenetic research and its clinical testing.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01GM092676-03
Application #
8311813
Study Section
Special Emphasis Panel (ZRG1-GGG-M (52))
Program Officer
Long, Rochelle M
Project Start
2010-07-15
Project End
2015-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
3
Fiscal Year
2012
Total Cost
$1,903,052
Indirect Cost
$503,950
Name
University of Washington
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Cole, Allison M; Stephens, Kari A; Keppel, Gina A et al. (2016) Extracting Electronic Health Record Data in a Practice-Based Research Network: Processes to Support Translational Research across Diverse Practice Organizations. EGEMS (Wash DC) 4:1206
Hart, Ragan; Veenstra, David L; Boudreau, Denise M et al. (2016) Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting. Am J Med :
Shirasaka, Y; Chaudhry, A S; McDonald, M et al. (2016) Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J 16:375-87
Fohner, Alison E; Wang, Zhican; Yracheta, Joseph et al. (2016) Genetics, Diet, and Season Are Associated with Serum 25-Hydroxycholecalciferol Concentration in a Yup'ik Study Population from Southwestern Alaska. J Nutr 146:318-25
Dorfman, E H; Cheng, E Y; Hebert, M F et al. (2016) Prenatal pharmacogenomics: a promising area for research. Pharmacogenomics J 16:303-4
Morales, Chelsea T; Muzquiz, LeeAnna I; Howlett, Kevin et al. (2016) Partnership with the Confederated Salish and Kootenai Tribes: Establishing an Advisory Committee for Pharmacogenetic Research. Prog Community Health Partnersh 10:173-83
O'Brien, Diane M; Thummel, Kenneth E; Bulkow, Lisa R et al. (2016) Declines in traditional marine food intake and vitamin D levels from the 1960s to present in young Alaska Native women. Public Health Nutr :1-8
Ryman, T K; Boyer, B B; Hopkins, S et al. (2015) Associations between diet and cardiometabolic risk among Yup'ik Alaska Native people using food frequency questionnaire dietary patterns. Nutr Metab Cardiovasc Dis 25:1140-5
Dorfman, Elizabeth H; Brown Trinidad, Susan; Morales, Chelsea T et al. (2015) Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas. Pharmacogenomics 16:227-37
Ryman, Tove K; Boyer, Bert B; Hopkins, Scarlett et al. (2015) Characterising the reproducibility and reliability of dietary patterns among Yup'ik Alaska Native people. Br J Nutr 113:634-43

Showing the most recent 10 out of 40 publications